Inoviq (ASX:IIQ) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IIQ Inoviq Ltd ASX:IIQ
27 GF Score
Price A$0.20
GF Value A$0.51
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Inoviq Net Loan?

Net Loan only applies to banks and insurance companies.

ASX:IIQ
27GF Score
Inoviq Ltd ASX:IIQ
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Inoviq (ASX:IIQ) Overvalued in 2026?

Based on GuruFocus' analysis, Inoviq stock appears to be undervalued. The current stock price of A$0.20 is trading 60.8% below its estimated GF Value™ of A$0.51. GuruFocus considers Inoviq to be Possible Value Trap.

Key valuation signals for ASX:IIQ:

  • Net Loan:
  • GF Value™: A$0.51 vs. price of A$0.20 (60.8% below fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inoviq Business Description

Other Exchanges EGQ0:GermanyEGQ0:Germany
Address 23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score

Get the complete analysis for ASX:IIQ

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.20
Price
A$0.51
GF Value